Chalkoo M, Bhat MY, Wani YH. Impact of liver metastasis on immunotherapy in gastric carcinoma. World J Gastrointest Surg 2024; 16(10): 3084-3086 [DOI: 10.4240/wjgs.v16.i10.3084]
Corresponding Author of This Article
Mohd Yaqoob Bhat, MBBS, MS, FNB Minimal Access Surgery Resident, Department of General Surgery, Government Medical College Srinagar, Kaksarai Karan Nagar, Srinagar 190010, Jammu and Kashmir, India. dryaqoob92@gmail.com
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Oct 27, 2024; 16(10): 3084-3086 Published online Oct 27, 2024. doi: 10.4240/wjgs.v16.i10.3084
Impact of liver metastasis on immunotherapy in gastric carcinoma
Mushtaq Chalkoo, Mohd Yaqoob Bhat, Yaser Hussain Wani
Mushtaq Chalkoo, Department of Surgery, Government Medical College, Srinagar 190014, Jammu and Kashmir, India
Mohd Yaqoob Bhat, Department of General Surgery, Government Medical College Srinagar, Srinagar 190010, Jammu and Kashmir, India
Yaser Hussain Wani, Post Graduate Department of Minimal Access and General Surgery, Government Medical College Srinagar, Srinagar 190010, Jammu and Kashmīr, India
Co-first authors: Mushtaq Chalkoo and Yaser Hussain Wani.
Author contributions: Chalkoo M, Bhat MY, and Wani YH designed the study; Bhat MY performed the research and typing; Wani YH performed the typing and editing the manuscript as well as analyzed the data; All authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Mohd Yaqoob Bhat, MBBS, MS, FNB Minimal Access Surgery Resident, Department of General Surgery, Government Medical College Srinagar, Kaksarai Karan Nagar, Srinagar 190010, Jammu and Kashmir, India. dryaqoob92@gmail.com
Received: March 19, 2024 Revised: May 24, 2024 Accepted: June 28, 2024 Published online: October 27, 2024 Processing time: 191 Days and 21.1 Hours
Abstract
The editorial discusses the impact of liver metastasis on immunotherapy efficacy in gastric cancer (GC) patients. Liver metastasis can hinder the effectiveness of immunotherapy by altering the immune microenvironment, leading to systemic loss of T-cells and reduced treatment response. Studies suggest that liver metastases serve as a negative baseline factor for immunotherapy efficacy, resulting in poorer progression-free survival and objective response rates. Strategies such as liver-mediated radiotherapy may help improve treatment outcomes by reshaping the liver’s immune microenvironment and reducing T-cell depletion. Understanding the complex interplay between liver metastasis and immunotherapy response is crucial for optimising patient care in GC.
Core Tip: Liver metastasis affects the systemic immune response, reducing the efficacy of immunotherapy for gastric cancer patients with liver metastases. According to studies, the presence of liver metastases reduces the effectiveness of immunotherapy by lowering progression-free survival and objective response rates. Strategies such as liver-mediated radiation may aid in improving treatment outcomes. Understanding the intricate interplay between the two is crucial for offering the best possible treatment for stomach cancer with liver metastases.
